Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3188 - Progression-Free Survival (PFS) and Site of First Progression in HER2+ Metastatic Breast Cancer (MBC) Patients (Pts) with (w) or without (w/o) Brain Metastases: A Pooled Analysis of Tucatinib Phase I Studies

Date

11 Sep 2017

Session

Poster display session

Presenters

Stacy Moulder

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

S. Moulder1, E. Hamilton2, C. Ferrario3, A. Conlin4, I. Krop5, M. Chamberlain6, T. Gray6, V. Borges7

Author affiliations

  • 1 Breast Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 37203 - Nashville/US
  • 3 Medical Oncology, Segal Cancer Center - Jewish General Hospital, H3T 1E2 - Montreal/CA
  • 4 Medical Oncology, Providence Cancer Center, 97213 - Portland/US
  • 5 Breast Oncology, Dana Farber Cancer Institute, 2115 - Boston/US
  • 6 Clinical Development, Cascadian Therapeutics, Inc., 98121 - Seattle/US
  • 7 Medical Oncology, University of Colorado Cancer Center, Aurora/US
More

Resources

Abstract 3188

Background

Brain metastases (BM) are frequent in HER2+ MBC occurring in > 30% of pts and are associated w significant neurologic morbidity and mortality. Current treatment strategies for BM primarily utilize radiotherapy (RT) and in selected instances surgical resection. Tucatinib is a highly selective oral HER2+ tyrosine kinase inhibitor that has shown promising results in HER2+ MBC both in pts w and w/o BM.

Methods

Two Phase 1b studies of tucatinib were pooled to compare PFS and sites of relapse in pts w or w/o BM.

Results

77 pts were analyzed, all treated at the recommended Phase 2 dose of 300mg PO BID of tucatinib, 50 in the 004 trial (tucatinib + T-DM1) and 27 in the 005 trial (tucatinib + trastuzumab + capecitabine). All pts were heavily pretreated w a median of 3 prior therapies including a taxane, trastuzumab, pertuzumab, T-DM1 and lapatinib. Four cohorts of pts were identified: 46% (35) had systemic metastases only, 17% (13) had previously treated (RT w or w/o surgery) and stable BM, 19% (15) had previously treated and progressive BM and 17% (13) had asymptomatic untreated BM demonstrated by screening MRI. Median PFS across cohorts was 8.5, 6.1, 9.0 and 7.1 months, respectively. No statistically significant difference in PFS was seen when comparing the non-BM cohort to all BM cohorts (median of 8.5 vs. 6.7 months; p = 0.65). The risk of progression in brain in pts w baseline BM was 48.8% overall (41.5% in brain only; 7.3% in brain and body) compared to an 11.1% overall (8.3% in brain only; 2.8% in brain and body) in pts w/o baseline BM.

Conclusions

54% of pts entered tucatinib studies w baseline BM, either previously treated (stable or progressive) or untreated. The cohorts of pts analyzed appear to differ only in the site of disease progression. Although pts w/o baseline BM primarily have progression in extraneural sites and pts w baseline BM primarily have progression in the CNS, PFS is comparable across cohorts. Furthermore, pts both w and w/o BM have durable responses w these combination therapies following multiple lines of prior HER2 targeted therapy. These data support the use of tucatinib in both pts w and w/o BM in the accruing HER2CLIMB trial.

Clinical trial identification

ONT-380-004 and ONT-380-005

Legal entity responsible for the study

Cascadian Therapeutics, Inc.

Funding

Cascadian Therapeutics, Inc.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.